Evidence map›Paper›PMID 36675516›Full record

ArticleJournal of clinical medicine2023

Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic Surgeons.

Thomas J Schnitzer, Rebecca L Robinson, Lars Viktrup, Joseph C Cappelleri, Andrew G Bushmakin, Leslie Tive, Mia Berry, Chloe Walker, James Jackson

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Thomas J SchnitzerFeinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.ORCID 0000-0002-4048-5431
Rebecca L RobinsonValue, Evidence and Outcomes, Eli Lilly and Company, Indianapolis, IN 46285, USA.ORCID 0000-0003-1490-0491
Lars ViktrupNeuroscience, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Joseph C CappelleriStatistical Research and Data Science Center, Pfizer Inc., New York, NY 10017, USA.
Andrew G BushmakinStatistical Research and Data Science Center, Pfizer Inc., New York, NY 10017, USA.
Leslie TiveInternal Medicine, Global Medical Affairs, Pfizer Inc., New York, NY 10017, USA.
Mia BerryReal World Research, Adelphi Real World, Bollington SK10 5JB, UK.
Chloe WalkerReal World Research, Adelphi Real World, Bollington SK10 5JB, UK.
James JacksonReal World Research, Adelphi Real World, Bollington SK10 5JB, UK.
Adelphi Group (United Kingdom) · GBPfizer (United States) · USEli Lilly (United States) · USNorthwestern University · US

Funding

Pfizer, Inc NA
6 · The paper itself

Abstract

Opioids are often prescribed for osteoarthritis (OA) pain, despite recommendations to limit use due to minimal benefits and associated harms. This study aimed to assess physicians' practice patterns and perceptions regarding opioids by specialty one year following the Centers for Disease Control and Prevention (CDC) published guidance on opioid prescribing. The 139/153 (90.8%) physicians who reported prescribing opioids in the previous year reported decreased prescribing for mild OA (51.3%, 26.5% and 33.3% of primary care physicians, rheumatologists, and orthopaedic surgeons, respectively), moderate OA (50.0%, 47.1% and 48.1%) and severe OA (43.6%, 41.2% and 44.4%). Prescribing changes were attributed to the CDC guidelines for 58.9% of primary care physicians, 59.1% of rheumatologists, and 73.3% of orthopaedic surgeons. Strong opioids were mostly reserved as third-line treatment. Although treatment effectiveness post-CDC guidelines was not assessed, perceptions of efficacy and quality of life with opioids significantly differed across specialties, whereas perceptions of safety, convenience/acceptability and costs did not. Physicians generally agreed on the barriers to opioid prescribing, with fear of addiction and drug abuse being the most important. Across specialties, physicians reported decreased opioid prescribing for OA, irrespective of OA severity, and in most cases attributed changes in prescribing to the CDC guideline.

Indexed as

addictioncenters for disease control and preventionprescription analgesicreal-world clinical practicetramadoltreatment guidelinestreatment patterns

Identifiers

PMID36675516
PMCPMC9864807
OpenAlexW4315700723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.